Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 10:03 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 481–504 of 732 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Carbohydrate 50% Clear all
Completed Not applicable Interventional Accepts healthy volunteers

Effect of a Modified Ketogenic-Mediterranean Diet on Alzheimer's Disease

NCT02984540
View directory record Official record
Conditions
Mild Cognitive Impairment, Insulin Resistance
Interventions
Low-Carbohydrate Diet, Low-Fat Diet
Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
50 Years to 85 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 28, 2025 · Synced Oct 15, 2026, 10:03 AM EDT
Terminated Phase 1 Interventional Results available

Vincristine, Doxorubicin, And Dexamethasone + Ixazomib in Acute Lymphoblastic Leukemia (ALL), Lymphoblastic Lymphoma Or Mixed Phenotype Acute Leukemia

NCT01887587
View directory record Official record
Conditions
Relapsed or Refractory Acute Lymphoblastic Leukemia, Relapsed or Refractory Lymphoblastic Lymphoma, Mixed Phenotype Acute Leukemia
Interventions
MLN9708, Vincristine, Doxorubicin, Dexamethasone
Drug
Lead sponsor
Ehab L Atallah
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jan 22, 2020 · Synced Oct 15, 2026, 10:03 AM EDT
Enrolling by invitation Phase 4 Interventional

Enhanced Recovery After Surgery (ERAS) in Live Donor Kidney Transplant Recipients

NCT06997016
View directory record Official record
Conditions
Postoperative Pain
Interventions
pre-operative carbohydrate drink, Acetaminophen, Gabapentin, Bupivacaine, Ambulation
Dietary Supplement · Drug · Other
Lead sponsor
Baylor Research Institute
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 15, 2026, 10:03 AM EDT
Completed Phase 4 Interventional Results available

Topiramate Treatment of Alcohol Use Disorders in Veterans With Post Traumatic Stress Disorder (PTSD): A Pilot Controlled Trial of Augmentation Therapy

NCT01087736
View directory record Official record
Conditions
PTSD, Alcohol Abuse, Alcoholism
Interventions
Topiramate, Placebo administration
Drug · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 3, 2014 · Synced Oct 15, 2026, 10:03 AM EDT
Completed Phase 4 Interventional Results available

Modafinil for Treatment of Fatigue in ALS Patients

NCT00614926
View directory record Official record
Conditions
Fatigue
Interventions
Modafinil, Placebo
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 80 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 20, 2012 · Synced Oct 15, 2026, 10:03 AM EDT
Withdrawn Phase 2 Interventional

Safety of Heparin in Patients With Septic Shock

NCT01234285
View directory record Official record
Conditions
Sepsis
Interventions
heparin
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 90 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated May 20, 2014 · Synced Oct 15, 2026, 10:03 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

A Comparison of Neuromuscular Recruitment in Trained and Untrained Adults

NCT06820658
View directory record Official record
Conditions
Healthy, Insulin Resistance
Interventions
Neuromuscular Test, DEXA, Mixed Meal Tolerance Test, Strength Test
Diagnostic Test
Lead sponsor
Mayo Clinic
Other
Eligibility
60 Years to 85 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Oct 15, 2026, 10:03 AM EDT
Completed Not applicable Interventional Results available

A Study to Determine Iatrogenic Hyperinsulinemia's Contribution to Insulin Resistance and Endothelial Dysfunction in Type 1 Diabetes

NCT04118374
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Standard Carb Diet, Low Carb Diet
Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 60 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 28, 2025 · Synced Oct 15, 2026, 10:03 AM EDT
Completed Phase 4 Interventional Results available

Effectiveness of Modafinil for Treating Fatigue in Adults With HIV/AIDS

NCT00118378
View directory record Official record
Conditions
HIV Infections, Fatigue
Interventions
Modafinil, Placebo
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 75 Years
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 10, 2017 · Synced Oct 15, 2026, 10:03 AM EDT
Completed Phase 1Phase 2 Interventional Results available

EPOCH Chemotherapy and Bortezomib for Associated T-Cell Leukemia Lymphoma

NCT01000285
View directory record Official record
Conditions
Leukemia-Lymphoma, Adult T-Cell
Interventions
Bortezomib, Etoposide, Vincristine, Doxorubicin, Prednisone, Cyclophosphamide, Raltegravir
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
6
States / cities
Miami, Florida • Baltimore, Maryland • St Louis, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2017 · Synced Oct 15, 2026, 10:03 AM EDT
Withdrawn Phase 2 Interventional

Comparing Standard of Care Chemotherapy Treatment to the Combination of Copanlisib and Olaparib for Recurrent Platinum Resistant Ovarian Cancer That Has Progressed Through PARP Inhibitor Therapy

NCT05295589
View directory record Official record
Conditions
Platinum-Refractory Fallopian Tube Carcinoma, Platinum-Refractory Ovarian Carcinoma, Platinum-Refractory Primary Peritoneal Carcinoma, Recurrent Fallopian Tube Endometrioid Adenocarcinoma, Recurrent Fallopian Tube High Grade Serous Adenocarcinoma, Recurrent Ovarian Endometrioid Adenocarcinoma, Recurrent Ovarian High Grade Serous Adenocarcinoma, Recurrent Platinum-Resistant Fallopian Tube Carcinoma, Recurrent Platinum-Resistant Ovarian Carcinoma, Recurrent Platinum-Resistant Primary Peritoneal Carcinoma, Recurrent Primary Peritoneal Endometrioid Adenocarcinoma, Recurrent Primary Peritoneal High Grade Serous Adenocarcinoma
Interventions
Computed Tomography, Copanlisib Hydrochloride, Magnetic Resonance Imaging, Olaparib, Paclitaxel, Pegylated Liposomal Doxorubicin Hydrochloride, Topotecan Hydrochloride
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
5
States / cities
Aurora, Colorado • Iowa City, Iowa • Cleveland, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 26, 2023 · Synced Oct 15, 2026, 10:03 AM EDT
Completed Phase 2 Interventional Results available

A Study of JNJ-70033093 (BMS-986177) Versus Subcutaneous Enoxaparin in Participants Undergoing Elective Total Knee Replacement Surgery

NCT03891524
View directory record Official record
Conditions
Arthroplasty, Replacement, Knee
Interventions
JNJ-70033093 25 mg, JNJ-70033093 50 mg, JNJ-70033093 100 mg, JNJ-70033093 200 mg, Placebo, Enoxaparin 40 mg
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
50 Years and older
Enrollment
1,242 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
9
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2025 · Synced Oct 15, 2026, 10:03 AM EDT
Terminated Phase 1Phase 2 Interventional

PTX-200, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide in Treating Patients With Stage IIB-IV Breast Cancer

NCT01697293
View directory record Official record
Conditions
Breast Adenocarcinoma, Estrogen Receptor Positive, HER2/Neu Negative, Recurrent Breast Carcinoma, Stage IIB Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer
Interventions
Cyclophosphamide, Doxorubicin Hydrochloride, Laboratory Biomarker Analysis, Paclitaxel, Therapeutic Conventional Surgery, Triciribine Phosphate
Drug · Other · Procedure
Lead sponsor
Prescient Therapeutics, Ltd.
Industry
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
2
States / cities
Tampa, Florida • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Sep 24, 2020 · Synced Oct 15, 2026, 10:03 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study of Atezolizumab in Combination With Either Obinutuzumab Plus Bendamustine or Obinutuzumab Plus (+) Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Participants With Follicular Lymphoma (FL) or Rituximab + CHOP in Participants With Diffuse Large B-Cell Lymphoma (DLBCL)

NCT02596971
View directory record Official record
Conditions
Diffuse Large B-Cell Lymphoma, Lymphoma Follicular
Interventions
Atezolizumab, Bendamustine, Cyclophosphamide, Doxorubicin, Obinutuzumab, Prednisone, Vincristine, Rituximab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
9
States / cities
Aurora, Colorado • Washington D.C., District of Columbia • Miami, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated May 24, 2021 · Synced Oct 15, 2026, 10:03 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Bioequivalence of the Metformin Component of the Fixed Dose Combination Tablet of Canagliflozin and Metformin Extended Release (XR) With Respect to Metformin XR Tablet Coadministered With Canagliflozin in Healthy Fed and Fasted Participants

NCT02851095
View directory record Official record
Conditions
Healthy
Interventions
Canagliflozin and Metformin Extended Release (XR) Fixed Dose Combination [FDC], Canagliflozin, Metformin Extended Release (XR)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Oct 15, 2026, 10:03 AM EDT
Completed Phase 4 Interventional Results available

An Open-Label, Single Arm Study of Obinutuzumab Short Duration Infusion in Patients With Previously Untreated Advanced Follicular Lymphoma

NCT03817853
View directory record Official record
Conditions
Advanced Follicular Lymphoma
Interventions
Obinutuzumab, Bendamustine, Cyclophosphamide, Doxorubicin, Prednisone/Prednisolone/Methylprednisolone, Vincristine
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
7
States / cities
Boulder, Colorado • Bethesda, Maryland • Florham Park, New Jersey + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2024 · Synced Oct 15, 2026, 10:03 AM EDT
Completed Phase 3 Interventional Results available

Docetaxel in Breast Cancer

NCT00312208
View directory record Official record
Conditions
Breast Cancer
Interventions
Docetaxel,doxorubicin, cyclophosphamide
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 70 Years · Female only
Enrollment
3,299 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2013
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 30, 2013 · Synced Oct 15, 2026, 10:03 AM EDT
Terminated Phase 1 Interventional

Proton Radiation Therapy With Cisplatin and Etoposide Followed by Surgery in Stage III Non-Small Cell Lung Cancer

NCT01565772
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Proton Beam Radiation, Cisplatin, Etoposide
Radiation · Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 17, 2016 · Synced Oct 15, 2026, 10:03 AM EDT
Terminated Early Phase 1 Interventional

Mirabegron in Achalasia: A Clinical and Manometric Proof of Concept Pilot Study

NCT03411252
View directory record Official record
Conditions
Achalasia
Interventions
Mirabegron 50 MG, Placebo
Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years to 75 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 24, 2021 · Synced Oct 15, 2026, 10:03 AM EDT
Completed Not applicable Interventional

Metabolism of Low Carbohydrate and Ketogenic Diet

NCT05071287
View directory record Official record
Conditions
Diabetic Kidney Disease, Cognitive Function, Weight Loss, Diabetic Control, Type2 Diabetes
Interventions
mHealth + low-fat diet, mHealth + low-carb/ketogenic diet
Other
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
2
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Feb 21, 2025 · Synced Oct 15, 2026, 10:03 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

The Effect of Sugar Sweetened and Diet Beverages Consumed as Part of a Weight-Maintenance Diet on Fat Storage

NCT02252952
View directory record Official record
Conditions
Focus: Understanding the Obesogenic Potential of Sugars and Non-caloric Sweeteners
Interventions
Beverage Consumption
Other
Lead sponsor
Rippe Lifestyle Institute
Industry
Eligibility
20 Years to 50 Years
Enrollment
99 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2013
U.S. locations
1
States / cities
Celebration, Florida
Source: ClinicalTrials.gov public record
Updated Dec 16, 2014 · Synced Oct 15, 2026, 10:03 AM EDT
Completed Phase 4 Interventional

Comparison of Low and Intermediate Dose Low-molecular-weight Heparin to Prevent Recurrent Venous Thromboembolism in Pregnancy

NCT01828697
View directory record Official record
Conditions
Deep Venous Thrombosis, Pulmonary Embolism
Interventions
Low dose nadroparin, Intermediate dose nadroparin, Low dose enoxaparin, Intermediate dose enoxaparin, Low dose dalteparin, Intermediate dose dalteparin, Fixed low dose tinzaparin, Intermediate dose tinzaparin
Drug
Lead sponsor
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
1,110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 26, 2022 · Synced Oct 15, 2026, 10:03 AM EDT
Completed Phase 2 Interventional Results available

Drug-drug Interaction Study

NCT01380743
View directory record Official record
Conditions
Pompe Disease
Interventions
duvoglustat, rhGAA
Drug
Lead sponsor
Amicus Therapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
11
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Orange, California + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2025 · Synced Oct 15, 2026, 10:03 AM EDT
Recruiting Phase 2 Interventional

Defining ctDNA Metrics in Posttransplant Lymphoproliferative Disorder (PTLD)

NCT06954805
View directory record Official record
Conditions
Lymphoma, Lymphoma, B-Cell
Interventions
Rituximab, Etoposide, Prednisone, Vincristine, Cyclophosphamide, Doxorubicin, CAPP-seq
Drug · Device
Lead sponsor
Jennifer Amengual
Other
Eligibility
15 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
2
States / cities
Stanford, California • New York, New York
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Oct 15, 2026, 10:03 AM EDT